RT Journal Article
SR Electronic
T1 Potassium para-aminobenzoate (potaba) in scleroderma
JF Drug and Therapeutics Bulletin
JO Drug Ther Bull
FD BMJ Publishing Group Ltd
SP 47
OP 48
DO 10.1136/dtb.6.12.47
VO 6
IS 12
YR 1968
UL http://dtb.bmj.com/content/6/12/47.abstract
AB In the past fifteen years there have been numerous reports on the treatment of scleroderma and related conditions with potassium para-aminobenzoate (Potaba - Glenwood Laboratories). The use of this ‘antifibrotic’ treatment is empirical. p-Aminobenzoic acid (PABA) is not known to affect fibrosis or fibrous tissue experimentally. Many bacteria require it for the synthesis of folic acid, and sulphonamides antagonise their utilisation of it.